Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 5
2008 5
2009 7
2010 6
2011 7
2012 6
2013 8
2014 6
2015 8
2016 12
2017 13
2018 14
2019 12
2020 14
2021 17
2022 10
2023 11
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

138 results

Results by year

Filters applied: . Clear all
Page 1
An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth.
Morgenstern A, Apostolidis C, Kratochwil C, Sathekge M, Krolicki L, Bruchertseifer F. Morgenstern A, et al. Among authors: bruchertseifer f. Curr Radiopharm. 2018;11(3):200-208. doi: 10.2174/1874471011666180502104524. Curr Radiopharm. 2018. PMID: 29732998 Free PMC article. Review.
Actinium-225-PSMA radioligand therapy of metastatic castration-resistant prostate cancer (WARMTH Act): a multicentre, retrospective study.
Sathekge MM, Lawal IO, Bal C, Bruchertseifer F, Ballal S, Cardaci G, Davis C, Eiber M, Hekimsoy T, Knoesen O, Kratochwil C, Lenzo NP, Mahapane J, Maserumule LC, Mdlophane AH, Mokoala KMG, Ndlovu H, Pant V, Rathke H, Reed J, Sen IB, Singh A, Sood A, Tauber R, Thakral P, Yadav MP, Morgenstern A. Sathekge MM, et al. Among authors: bruchertseifer f. Lancet Oncol. 2024 Feb;25(2):175-183. doi: 10.1016/S1470-2045(23)00638-1. Epub 2024 Jan 11. Lancet Oncol. 2024. PMID: 38218192
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
Feuerecker B, Tauber R, Knorr K, Heck M, Beheshti A, Seidl C, Bruchertseifer F, Pickhard A, Gafita A, Kratochwil C, Retz M, Gschwend JE, Weber WA, D'Alessandria C, Morgenstern A, Eiber M. Feuerecker B, et al. Among authors: bruchertseifer f. Eur Urol. 2021 Mar;79(3):343-350. doi: 10.1016/j.eururo.2020.11.013. Epub 2020 Dec 5. Eur Urol. 2021. PMID: 33293081
Targeted alpha therapy for glioblastoma.
Kunikowska J, Morgenstern A, Pełka K, Bruchertseifer F, Królicki L. Kunikowska J, et al. Among authors: bruchertseifer f. Front Med (Lausanne). 2022 Dec 16;9:1085245. doi: 10.3389/fmed.2022.1085245. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36590948 Free PMC article. Review.
Targeted α-Therapy Using 225Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment.
Ertveldt T, Krasniqi A, Ceuppens H, Puttemans J, Dekempeneer Y, Jonghe K, Mey W, Lecocq Q, Vlaeminck Y, Awad RM, Goyvaerts C, Veirman K, Morgenstern A, Bruchertseifer F, Keyaerts M, Devoogdt N, D'Huyvetter M, Breckpot K. Ertveldt T, et al. Among authors: bruchertseifer f. J Nucl Med. 2023 May;64(5):751-758. doi: 10.2967/jnumed.122.264752. Epub 2023 Apr 13. J Nucl Med. 2023. PMID: 37055223
Supply and Clinical Application of Actinium-225 and Bismuth-213.
Morgenstern A, Apostolidis C, Bruchertseifer F. Morgenstern A, et al. Among authors: bruchertseifer f. Semin Nucl Med. 2020 Mar;50(2):119-123. doi: 10.1053/j.semnuclmed.2020.02.003. Epub 2020 Feb 21. Semin Nucl Med. 2020. PMID: 32172796 Free PMC article. Review.
225Ac- and 213Bi-Substance P Analogues for Glioma Therapy.
Królicki L, Kunikowska J, Bruchertseifer F, Koziara H, Królicki B, Jakuciński M, Pawlak D, Rola R, Morgenstern A, Rosiak E, Merlo A. Królicki L, et al. Among authors: bruchertseifer f. Semin Nucl Med. 2020 Mar;50(2):141-151. doi: 10.1053/j.semnuclmed.2019.11.004. Semin Nucl Med. 2020. PMID: 32172799 Free article. Review.
138 results